What is Supernus Pharmaceuticals's SG&A?

Supernus Pharmaceuticals (SUPN) reported SG&A of $125.17M in Q1 2026.

How has Supernus Pharmaceuticals's SG&A changed year-over-year?

Supernus Pharmaceuticals's SG&A increased by 39.2% year-over-year, from $89.94M to $125.17M.

What is the long-term trend for Supernus Pharmaceuticals's SG&A?

Over 4 years (2021 to 2025), Supernus Pharmaceuticals's SG&A has grown at a 12.3% compound annual growth rate (CAGR), from $304.76M to $485.56M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Supernus Pharmaceuticals SUPN SG&A

SG&A at other companies

AbbVieABBV

$3.58B+8.7%

Rapport Therapeutics, Inc.RAPP

$11.5M+52.6%

Axsome TherapeuticsAXSM

$185M+53.2%

Neurocrine BiosciencesNBIX

$318.5M+15.2%

Jazz PharmaceuticalsJAZZ

$352.7M-31.4%

Acadia PharmaceuticalsACAD

$171.02M+35.3%

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's SG&A?: Supernus Pharmaceuticals (SUPN) reported SG&A of $125.17M in Q1 2026.
How has Supernus Pharmaceuticals's SG&A changed year-over-year?: Supernus Pharmaceuticals's SG&A increased by 39.2% year-over-year, from $89.94M to $125.17M.
What is the long-term trend for Supernus Pharmaceuticals's SG&A?: Over 4 years (2021 to 2025), Supernus Pharmaceuticals's SG&A has grown at a 12.3% compound annual growth rate (CAGR), from $304.76M to $485.56M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.